MARSHALL UNIVERSITY

Lofexidine Trial Launched for Neonatal Opioid Withdrawal Syndrome

- Marshall University is conducting a clinical trial to assess oral lofexidine, a non-opioid medication, for treating Neonatal Opioid Withdrawal Syndrome (NOWS). - The Phase 2 trial aims to evaluate the safety and pharmacokinetics of lofexidine in newborns exposed to opioids prenatally. - Unlike opioid-based treatments, lofexidine does not produce euphoria or addiction potential, offering a potentially safer alternative. - The study will monitor NOWS symptoms using the Modified Finnegan Neonatal Abstinence Scoring Tool (mFNAST) and assess treatment duration.